C2i Genomics, Karkinos Healthcare partner to bring AI-powered cancer R&D to India

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

C2i Genomics and Karkinos Healthcare have partnered to co-develop the minimal residual disease market in India. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The National Institute for Health Care Management Foundation is now accepting letters of inquiry for the 2025-2026 funding cycle of NIHCM Foundation’s Research Grant program. We will be awarding a total of $500,000 in grants to support innovative, independent, investigator-initiated research that has the potential to inform managed care organizations, policymakers, and related stakeholders to improve the affordability and quality of U.S. health care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login